(Fox Business) Johnson & Johnson said it is starting its Phase 1/2a trial of its Covid-19 vaccine in the second half of July, earlier than initially planned.
The trial will evaluate patients’ response to vaccination and immune response. It will involve 1,045 healthy adults aged 18 to 55, as well as adults aged 65 and above, J&J said.
The study will be held in the U.S. and Belgium, the company said.